About Avanir
Avanir is a company based in Aliso Viejo (United States) founded in 1988 was acquired by Otsuka in December 2014. Avanir operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
- Headquarter Aliso Viejo, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avanir Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Avanir
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Board Team
8 people
Software Development Team
7 people
Product Management Team
6 people
Sales and Marketing
5 people
Senior Team
5 people
Human Resources and Administration
4 people
Health Team
3 people
Unlock access to complete
Funding Insights of Avanir
Investors in Avanir
Avanir has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Otsuka and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked | |
|
Generic pharmaceuticals and nutraceuticals are manufactured and marketed by Otsuka.
|
Locked | Locked | Locked |
Investor details for Avanir
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avanir
Investment portfolio details for Avanir
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avanir
Detailed financials for Avanir
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avanir Comparisons
Peer comparison for Avanir
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avanir
Avanir operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapies for psychosis and cognitive impairment are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Avanir
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avanir
Complete news archive for Avanir
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avanir
Avanir was founded in 1988 and raised its 1st funding round 24 years after it was founded.
Avanir is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.
Wa El Hashad is the current CEO of Avanir.
Avanir Pharmaceuticals was established in 1988 in Aliso Viejo, United States, as a biopharmaceutical entity. Focus is placed on acquiring, developing, and commercializing treatments for central nervous system disorders. Nuedexta, approved by the FDA for pseudobulbar affect, and Onzetra Xsail, for acute migraine treatment in adults, are marketed. AVP-786 is under clinical development for conditions including Alzheimers disease, depression, and schizophrenia.
Avanir's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Avanir has 3 investors. Key investors include SVB, Otsuka, and Oxford Finance.